Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | PNMT | P11086 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 2/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22817597 | 1.00 | CNR2 (0.58) | CNR2PNMTKDM4EMEN1KMT2A | |
| SCHEMBL30034816 | 1.00 | CNR2 (0.58) | CNR2PNMTKDM4EMEN1KMT2A | |
| SCHEMBL30353293 | 1.00 | CNR2 (0.58) | CNR2PNMTKDM4EMEN1KMT2A | |
| SCHEMBL22817603 | 1.00 | CNR2 (0.58) | CNR2PNMTKDM4EMEN1KMT2A | |
| SCHEMBL22817612 | 0.84 | KDM4E (0.47) | CNR2PNMTKDM4EMEN1KMT2A | |
| SCHEMBL30034139 | 0.84 | KDM4E (0.47) | CNR2PNMTKDM4EMEN1KMT2A | |
| SCHEMBL22817610 | 0.84 | KDM4E (0.47) | CNR2PNMTKDM4EMEN1KMT2A | |
| SCHEMBL28168728 | 0.82 | MEN1 (0.54) | CNR2KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25304558 | 0.82 | PNMT (0.64) | PNMTCETPACP3GRIN2B | |
| SCHEMBL13993320 | 0.81 | KDM4E (0.70) | CNR2KDM4EMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560367-B2 | Pyrrolidinones and a process to prepare them | FMC CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210107890-A1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | FMC CORPORATION | 2021-04-15 | — | — | US | disclosed |
| US-10875838-B2 | Pyrrolidinones and a process to prepare them | FMC CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875838-B2 | Pyrrolidinones and a process to prepare them | CCNB1, CCNA2, F2 | CNR2 1503/4885PNMT 709/4885KDM4E 1079/4885 |
| US-20210107890-A1 | PYRROLIDINONES AND A PROCESS TO PREPARE THEM | CCNB1, CCNA2, F2 | CNR2 1503/4885PNMT 709/4885KDM4E 1079/4885 |
| US-11560367-B2 | Pyrrolidinones and a process to prepare them | CCNB1, CCNA2, F2 | CNR2 1503/4885PNMT 709/4885KDM4E 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.